BACKGROUND: Carbapenems are commonly used in hospitalized infants despite a lack of complete safety data and associations with seizures in older children. We compared the incidence of adverse events in hospitalized infants receiving meropenem versus imipenem/cilastatin. METHODS: We conducted a retrospective cohort study of 5566 infants treated with meropenem or imipenem/cilastatin in neonatal intensive care units managed by the Pediatrix Medical Group between 1997 and 2010. Multivariable conditional logistic regression was performed to evaluate the association between carbapenem therapy and adverse events, controlling for infant factors and severity of illness. RESULTS: Adverse events were more common with use of meropenem compared with imipenem/cilastatin (62.8/1000 infant days versus 40.7/1000 infant days, P < 0.001). There was no difference in seizures with meropenem versus imipenem/cilastatin (adjusted odds ratio 0.96; 95% confidence interval: 0.68, 1.32). The incidence of death, as well as the combined outcome of death or seizure, was lower with meropenem use-odds ratio 0.68 (0.50, 0.88) and odds ratio 0.77 (0.62, 0.95), respectively. CONCLUSION: In this cohort of infants, meropenem was associated with more frequent but less severe adverse events when compared with imipenem/cilastatin.
BACKGROUND: Carbapenems are commonly used in hospitalized infants despite a lack of complete safety data and associations with seizures in older children. We compared the incidence of adverse events in hospitalized infants receiving meropenem versus imipenem/cilastatin. METHODS: We conducted a retrospective cohort study of 5566 infants treated with meropenem or imipenem/cilastatin in neonatal intensive care units managed by the Pediatrix Medical Group between 1997 and 2010. Multivariable conditional logistic regression was performed to evaluate the association between carbapenem therapy and adverse events, controlling for infant factors and severity of illness. RESULTS: Adverse events were more common with use of meropenem compared with imipenem/cilastatin (62.8/1000 infant days versus 40.7/1000 infant days, P < 0.001). There was no difference in seizures with meropenem versus imipenem/cilastatin (adjusted odds ratio 0.96; 95% confidence interval: 0.68, 1.32). The incidence of death, as well as the combined outcome of death or seizure, was lower with meropenem use-odds ratio 0.68 (0.50, 0.88) and odds ratio 0.77 (0.62, 0.95), respectively. CONCLUSION: In this cohort of infants, meropenem was associated with more frequent but less severe adverse events when compared with imipenem/cilastatin.
Authors: Timothy C Fabian; Thomas M File; John M Embil; Jacobus E J Krige; Stanley Klein; Andrea Rose; David Melnick; Norberto E Soto Journal: Surg Infect (Larchmt) Date: 2005 Impact factor: 2.150
Authors: H L Hsu; C Y Lu; H Y Tseng; P I Lee; H P Lai; W C Lin; Y C Hsieh; C Y Lee; L M Huang Journal: J Microbiol Immunol Infect Date: 2001-12 Impact factor: 4.399
Authors: April D Miller; Amanda M Ball; P Brandon Bookstaver; Emily K Dornblaser; Charles L Bennett Journal: Pharmacotherapy Date: 2011-04 Impact factor: 4.705
Authors: C M Odio; J R Puig; J M Feris; W N Khan; W J Rodriguez; G H McCracken; J S Bradley Journal: Pediatr Infect Dis J Date: 1999-07 Impact factor: 2.129
Authors: R Fujii; H Meguro; O Arimasu; H Yoshioka; K Fujita; S Maruyama; F Inyaku; I Nagamatsu; Y Wagatsuma; A Takase Journal: Jpn J Antibiot Date: 1986-07
Authors: John N van den Anker; Pavla Pokorna; Martina Kinzig-Schippers; Jirina Martinkova; Ronald de Groot; G L Drusano; Fritz Sorgel Journal: Antimicrob Agents Chemother Date: 2009-07-06 Impact factor: 5.191
Authors: Michael Cohen-Wolkowiez; Brenda Poindexter; Margarita Bidegain; Joern-Hendrik Weitkamp; Robert L Schelonka; David A Randolph; Robert M Ward; Kelly Wade; Gloria Valencia; David Burchfield; Antonio Arrieta; Varsha Mehta; Michele Walsh; Anand Kantak; Maynard Rasmussen; Janice E Sullivan; Neil Finer; Wade Rich; Beverly S Brozanski; John van den Anker; Jeffrey Blumer; Matthew Laughon; Kevin M Watt; Gregory L Kearns; Edmund V Capparelli; Karen Martz; Katherine Berezny; Daniel K Benjamin; P Brian Smith Journal: Clin Infect Dis Date: 2012-09-05 Impact factor: 9.079
Authors: Laura E Miller; Chris DeRienzo; P Brian Smith; Carl Bose; Reese H Clark; C Michael Cotten; Daniel K Benjamin; Chi D Hornik; Rachel G Greenberg Journal: J Perinatol Date: 2020-10-08 Impact factor: 2.521
Authors: Grace Li; Joseph F Standing; Julia Bielicki; William Hope; John van den Anker; Paul T Heath; Mike Sharland Journal: Drugs Date: 2017-06 Impact factor: 9.546
Authors: Christoph P Hornik; Andrew M Atz; Catherine Bendel; Francis Chan; Kevin Downes; Robert Grundmeier; Ben Fogel; Debbie Gipson; Matthew Laughon; Michael Miller; Michael Smith; Chad Livingston; Cindy Kluchar; Anne Heath; Chanda Jarrett; Brian McKerlie; Hetalkumar Patel; Christina Hunter Journal: Appl Clin Inform Date: 2019-05-08 Impact factor: 2.342
Authors: Christopher J Arnold; Jessica Ericson; Nathan Cho; James Tian; Shelby Wilson; Vivian H Chu; Christoph P Hornik; Reese H Clark; Daniel K Benjamin; P Brian Smith Journal: Pediatr Infect Dis J Date: 2015-09 Impact factor: 3.806
Authors: Christoph P Hornik; Daniel K Benjamin; P Brian Smith; Michael J Pencina; Adriana H Tremoulet; Edmund V Capparelli; Jessica E Ericson; Reese H Clark; Michael Cohen-Wolkowiez Journal: J Pediatr Date: 2016-08-10 Impact factor: 6.314